Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04739280 · ClinicalTrials.gov registry record
Women's Assessed Cardiovascular Evaluation With MCG
A clinical trial, sponsored by Genetesis.
- Completed
- Registry status
- 32
- Enrollment target
NCT04739280 is a clinical trial that has completed, run by Genetesis. The registered enrollment target is 32 participants.
The verdict
NCT04739280 has completed, sponsored by Genetesis.
- COMPLETED
- Registry status
- 32 participants
- Enrollment target
Study Summary
Cardiovascular disease (CVD) is the number one cause of death for women over the age of 25, accounting for 1 of every 3 female deaths. Research has shown that while hypertension in women is less controlled, they are also less likely to be identified with ischemic heart disease and when diagnosed treated less aggressively than men. Moreover, women who are diagnosed with breast cancer have an increased risk for cardiovascular disease. The Women's Assessed Cardiovascular Evaluation with MCG (WACE-MCG) study is designed to collect CardioFlux scans on a select group of female volunteers who are Ms. Medicine patients. CardioFlux is used as a noninvasive MCG tool that analyzes and records the magnetic fields of the heart to detect various forms of heart disease. There will be a 12-month duration of the study where we propose to collect screening data from approximately 200 volunteers who present to the Genetesis facility for a 5-minute CardioFlux MCG scan. The volunteers will be contacted at intervals over a 1-year period for follow-up data and may choose whether or not they would like to provide follow-up data or participate in another scan.
Interventions
- DEVICE CardioFlux Magnetocardiography
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2020-10-15 |
| Est. Completion | 2022-07-21 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04739280
The ClinicalTrials.gov registry entry for NCT04739280 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genetesis, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CardioFlux Magnetocardiography is the first listed.
NCT04739280 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04739280 about?
NCT04739280 is a clinical study titled "Women's Assessed Cardiovascular Evaluation With MCG". Cardiovascular disease (CVD) is the number one cause of death for women over the age of 25, accounting for 1 of every 3 female deaths. Research has shown that while hypertension in women is less controlled, they are also less likely to be identified with ischemic heart disease and when diagnosed tre...
What is the current status of trial NCT04739280?
This trial is currently completed. The enrollment target is 32 participants. The study started on 2020-10-15. Estimated completion is 2022-07-21.
What interventions are being tested in trial NCT04739280?
The interventions under investigation include: CardioFlux Magnetocardiography (DEVICE).
Who is sponsoring clinical trial NCT04739280?
This trial is sponsored by Genetesis, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.